Role of fusogenic non-PC liposomes in elicitation of protective immune response against experimental murine salmonellosis.
Earlier we have demonstrated that novel fusogenic liposomes made up of lipid from Escherichia coli (escheriosomes) have strong tendency to fuse with the plasma membrane of target cells and thereby delivering the entrapped contents into their cytosol. The delivery of entrapped antigen in cytosol of the target cells ensues its processing and presentation along with MHC class I pathway that eventually elicit antigen specific cytotoxic T cells. The result of the present study revealed that immunization of BALB/c mice with escheriosome-encapsulated Salmonella typhimurium (S. typhimurium) cytosolic antigens resulted in the augmentation of antigen specific cytotoxic T cell lymphocyte as well as IgG responses. In contrast, free or conventional liposome (PC liposome) encapsulated antigen failed to induce CD8+ CTLs in the immunized animals. Further, immunization with escheriosome-encapsulated antigen resulted in significant enhancement in the release of IFN-gamma and IgG2a in the experimental animals. Interestingly, the immunization with escheriosome-encapsulated antigen resulted in upregulation of CD80 and CD86 on the surface of antigen presenting cells (APCs) as well. Finally, the results of the present study reveal that immunization of animals with escheriosomes encapsulated antigen protected them against virulent S. typhimurium infection. This was evident by increased survival, and reduced bacterial burden in vital organs of the immunized animals. The data of the present study suggest that escheriosomes can emerge as an effective vehicle for intracellular delivery of antigen and thus hold promise in development of liposome based vaccine against Salmonella and other intracellular pathogens.
Ahmad
N
N
Faculty of Pharmacy, Jamia Hamdard, New Delhi 62, India.
Deeba
F
F
Faisal
S M
SM
Khan
A
A
Agrewala
J N
JN
Dwivedi
V
V
Owais
M
M
D000276:Adjuvants, Immunologic; D000818:Animals; D000942:Antigens, Bacterial / Q000008:administration & dosage* / Q000276:immunology; D018122:B7-1 Antigen / Q000276:immunology; D051940:B7-2 Antigen / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D049109:Cell Proliferation; D003600:Cytosol / Q000378:metabolism; D004195:Disease Models, Animal; D005260:Female; D008081:Liposomes; D051379:Mice; D008807:Mice, Inbred BALB C; D012481:Salmonella Infections, Animal / Q000276:immunology / Q000517:prevention & control*; D022562:Salmonella Vaccines / Q000008:administration & dosage* / Q000276:immunology; D012486:Salmonella typhimurium / Q000472:pathogenicity
D000276:Adjuvants, Immunologic; D000942:Antigens, Bacterial; D018122:B7-1 Antigen; D051940:B7-2 Antigen; D008081:Liposomes; D022562:Salmonella Vaccines